<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04584918</url>
  </required_header>
  <id_info>
    <org_study_id>INNV-BHT1000-001</org_study_id>
    <nct_id>NCT04584918</nct_id>
  </id_info>
  <brief_title>An Open Label Study to Assess the Effect of Euryco-10® Oral Dietary Supplement in Senior Men</brief_title>
  <official_title>An Open Label Study to Assess the Effect of Euryco-10® Oral Dietary Supplement on Total Testosterone, Sex Drive and Energy Level in Senior Men</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innovus Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Innovus Pharmaceuticals, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the effect and support the tolerance of orally ingested formulation containing&#xD;
      Eurycoma longifolia dietary supplement (Euryco-10) on a cohort of senior men.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-center, single arm, open label study in senior men. This study will&#xD;
      investigate the effect and tolerance of oral ingestion of Euryco-10. Subjects meeting all&#xD;
      inclusion and none of the exclusion criteria will be enrolled and provided with study dietary&#xD;
      supplement. Subjects will be instructed to take 2 capsules per day for 35 days.&#xD;
      Administration and any adverse events will be recorded in the subject diary. At each clinic&#xD;
      visit (Day 0, Day 21 and Day 35) the Subject will complete the AMS Questionnaire.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2020</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in serum total testosterone concentration compared to baseline</measure>
    <time_frame>Day 0, Day 21 and Day 35</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Q 9 of the AMS Questionnaire</measure>
    <time_frame>Day 0, Day 21 and Day 35</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Q17 of the AMS Questionnaire</measure>
    <time_frame>Day 0, Day 21 and Day 35</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Healthy Aging</condition>
  <eligibility>
    <study_pop>
      <textblock>
        community sample&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Male ≥ 55 years of age&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Severe lower urinary tract symptoms.&#xD;
&#xD;
        Current use of any herbal and/or nutritional supplements that can interfere with&#xD;
        testosterone.&#xD;
&#xD;
        A history of cancer except melanoma skin cancer.&#xD;
&#xD;
        Currently receiving treatment with cancer chemotherapy or antiandrogens.&#xD;
&#xD;
        Chronic use of systemic glucocorticoids (use within &gt;14 days up to the 3months prior to&#xD;
        screening); use of non-testosterone anabolic steroids within12 months prior to screening.&#xD;
&#xD;
        History of frequent opioid use &gt;1 time/week during any week within 30 days prior to&#xD;
        screening.&#xD;
&#xD;
        Have a history of known angina.&#xD;
&#xD;
        Have a history of severe liver disease or clinical evidence of hepatic impairment at&#xD;
        screening.&#xD;
&#xD;
        Untreated severe obstructive sleep apnea.&#xD;
&#xD;
        Allergies to any of the ingredients in Euryco-10® or BioPerine.&#xD;
&#xD;
        Any condition which would interfere with the subject's ability to provide informed consent,&#xD;
        to comply with study instructions, or which might confound the interpretation of the study&#xD;
        results&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>San Diego Sexual Medicine</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92120</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Jo Anna Williams</last_name>
      <phone>619-265-7695</phone>
      <email>jwilliams@sdsm.info</email>
    </contact>
    <investigator>
      <last_name>Irwin Goldstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 8, 2020</study_first_submitted>
  <study_first_submitted_qc>October 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 14, 2020</study_first_posted>
  <last_update_submitted>October 8, 2020</last_update_submitted>
  <last_update_submitted_qc>October 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

